Faculty of Pharmacy, Department of Pharmacy Division of Pharmacotherapeutics (Shiba-Kyoritsu)


Associate Professor

E-mail Address

E-mail address

Related Websites

External Links


Research Areas 【 Display / hide

  • Tumor diagnostics

  • Gastroenterology

Research Keywords 【 Display / hide

  • microRNA

  • extracellular RNA

  • cancer


Books 【 Display / hide

  • 血中マイクロRNAを用いた膵がん診断の展望. 早期発見・予防に向けた次世代がん検査技術の最前線

    松﨑潤太郎, シーエムシー出版, 2019

  • 胃・十二指腸潰瘍. 看護基礎教育テキスト ナーシング・グラフィカ「疾患と看護シリーズ」『3 消化器疾患と看護』

    松﨑潤太郎, 鈴木秀和, メディカ出版, 2019

  • がん早期診断. テクノロジーロードマップ2019-2028 医療・健康・食農編

    松﨑潤太郎, 落谷孝広, 日経BP, 2019

  • Bile acids and esophageal cancer

    J Matsuzaki, H Suzuki, 2017

  • エクソソームに着目した新しい診断技術の開発. 早期発見・低侵襲で見つけ出す疾患・病態検査・診断法の開発 ~がん、認知症、感染症、難病、糖尿病、リウマチ、希少疾患~

    松﨑潤太郎, 落谷孝広, 技術情報協会, 2017

display all >>

Papers 【 Display / hide

  • Extracellular microRNA profiling for prognostic prediction in patients with high‐grade serous ovarian carcinoma

    Kosuke Yoshida and Akira Yokoi and Juntaro Matsuzaki and Tomoyasu Kato and Takahiro Ochiya and Hiroaki Kajiyama and Yusuke Yamamoto

    Cancer Science (Wiley)   2021.10

    ISSN  1347-9032

     View Summary

    High-grade serous ovarian carcinoma is a leading cause of death in female patients worldwide. MicroRNAs (miRNAs) are stable noncoding RNAs in the peripheral blood that reflect a patient’s condition, and therefore, they have received substantial attention as noninvasive biomarkers in various diseases. We previously reported the usefulness of serum miRNAs as diagnostic biomarkers. Here, we investigated the prognostic impact of the serum miRNA profile. We used the GSE106817 dataset, which included preoperative miRNA profiles of patients with ovarian malignancies. Excluding patients with other malignancy or insufficient prognostic information, we included 175 patients with high-grade serous ovarian carcinoma. All patients except four underwent surgery and received chemotherapy as initial treatment. The median follow-up period was 54.6 months (range, 3.5-144.1 months). Univariate Cox regression analysis revealed that higher levels of miR-187-5p and miR-6870-5p were associated with both poorer progression-free survival (PFS) and overall survival (OS), and miR-1908-5p, miR-6727-5p, and miR-6850-5p were poor prognostic indicators of PFS. The OS and PFS prognostic indices were then calculated using the expression values of three prognostic miRNAs. Multivariate Cox regression analysis showed that both indices were significantly independent poor prognostic factors (hazard ratio for OS and PFS, 2.343 [P =.015] and 2.357 [P =.005], respectively). In conclusion, circulating miRNA profiles can potentially provide information to predict the prognosis of patients with high-grade serous ovarian carcinoma. Therefore, there is a strong demand for early clinical application of circulating miRNAs as noninvasive biomarkers.

  • Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review

    H Tominaga, J Matsuzaki, C Oikawa, K Toyoshima, H Manabe, E Ozawa, ...

    Cancers 13 (16), 4220 (Cancers)  13 ( 16 )  2021.08

     View Summary

    Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.

  • Early prediction of COVID-19 severity using extracellular vesicle COPB2.

    Fujita Y, Hoshina T, Matsuzaki J, Yoshioka Y, Kadota T, Hosaka Y, Fujimoto S, Kawamoto H, Watanabe N, Sawaki K, Sakamoto Y, Miyajima M, Lee K, Nakaharai K, Horino T, Nakagawa R, Araya J, Miyato M, Yoshida M, Kuwano K, Ochiya T

    Journal of extracellular vesicles (Journal of Extracellular Vesicles)  10 ( 8 ) e12092 2021.06

     View Summary

    The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID-19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00-1.00)). The validation set included 40 COVID-19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73-0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy.

  • A novel combination of serum microRNAs for the detection of early gastric cancer

    S Abe, J Matsuzaki, K Sudo, I Oda, H Katai, K Kato, S Takizawa, ...

    Gastric Cancer, 1-9 (Gastric Cancer)  24 ( 4 ) 835 - 843 2021.03

    ISSN  1436-3291

     View Summary

    Background: The aim of this study was to identify serum miRNAs that discriminate early gastric cancer (EGC) samples from non-cancer controls using a large cohort. Methods: This retrospective case–control study included 1417 serum samples from patients with EGC (seen at the National Cancer Center Hospital in Tokyo between 2008 and 2012) and 1417 age- and gender-matched non-cancer controls. The samples were randomly assigned to discovery and validation sets and the miRNA expression profiles of whole serum samples were comprehensively evaluated using a highly sensitive DNA chip (3D-Gene ) designed to detect 2565 miRNA sequences. Diagnostic models were constructed using the levels of several miRNAs in the discovery set, and the diagnostic performance of the model was evaluated in the validation set. Results: The discovery set consisted of 708 samples from EGC patients and 709 samples from non-cancer controls, and the validation set consisted of 709 samples from EGC patients and 708 samples from non-cancer controls. The diagnostic EGC index was constructed using four miRNAs (miR-4257, miR-6785-5p, miR-187-5p, and miR-5739). In the discovery set, a receiver operating characteristic curve analysis of the EGC index revealed that the area under the curve (AUC) was 0.996 with a sensitivity of 0.983 and a specificity of 0.977. In the validation set, the AUC for the EGC index was 0.998 with a sensitivity of 0.996 and a specificity of 0.953. Conclusions: A novel combination of four serum miRNAs could be a useful non-invasive diagnostic biomarker to detect EGC with high accuracy. A multicenter prospective study is ongoing to confirm the present observations. ®

  • Precision medicine approaches to prevent gastric cancer

    J Matsuzaki, H Tsugawa, H Suzuki

    Gut and Liver 15 (1), 3 (Gut and Liver)  15 ( 1 ) 3 - 12 2021.01

    ISSN  1976-2283

     View Summary

    © Gut and Liver. Gastric cancer remains one of the most common causes of cancer-related death worldwide, although the incidence is declining gradually. The primary risk factor for gastric cancer is Helicobacter pylori infection. The Kyoto global consensus report recommends eradication of H. pylori in all infected patients. However, because it is difficult to stratify the risk of carcinogenesis among patients with a history of H. pylori infection, annual endoscopic surveillance is performed for everyone after eradication. This review summarizes the current approaches used to screen for novel molecules that could assist in the diagnosis of gastric cancer and reduce mortality. Most well-studied molecules are tissue protein biomarkers expressed by the gastric epithelium and associated with metaplasia-dysplasia-carcinoma sequences. Other strategies focus on the origin of cancer stem cell-related markers, such as CD44, and immune reaction-related markers, such as matrix metallopeptidases. Noninvasive methods such as blood-based approaches are more attractive. Serum pepsinogen levels predict the severity of gastric mucosal atrophy before H. pylori eradication, whereas plasma ghrelin levels are associated with atrophy even after eradication. Cell-free DNAs and RNAs are attractive tools for the early detection of cancer. These ideas could lead to the development of more personalized strategies for cancer prevention based on cutting-edge technologies.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 腫瘍マーカーによるがんの統合的層別化 血中miRNA診断技術開発の現状と未来

    松崎 潤太郎

    日本分子腫瘍マーカー研究会プログラム・講演抄録 (日本分子腫瘍マーカー研究会)  41回   17 - 17 2021.09

  • 自発走運動の継続および中止がマウス脂肪組織の老化関連遺伝子発現に及ぼす影響

    木村 真規, 鈴木 聖矢, 森谷 淳司, 野上 和幹, 内田 諒英, 松崎 潤太郎, 齋藤 義正, 齋藤 英胤

    日本抗加齢医学会総会プログラム・抄録集 ((一社)日本抗加齢医学会)  21回   197 - 197 2021.06

  • いま知っておきたい最新の臨床検査 身近な疾患を先端技術で診断(Vol.2) 血液検査によるがん診断の展望

    堀江 沙良, 落谷 孝広, 松崎 潤太郎

    医学のあゆみ (医歯薬出版(株))  277 ( 2 ) 193 - 198 2021.04

    ISSN  0039-2359

     View Summary

    リキッドバイオプシーとは、血液などの体液の採取によって病理診断に匹敵する精度で疾患診断しうるものと期待される新技術である。その解析標的には細胞外DNA、microRNA、血中循環腫瘍細胞、エクソソーム、tumor-educated platelets(TEPs)などがあげられる。がんの早期診断、治療方針の最適化や治療後のモニタリングへの有用性が期待される。いずれの標的も検出方法や評価方法が十分には成熟しておらず、臨床応用に向けて技術開発が進められている。臨床において長く使用されている腫瘍マーカーに加え、現在開発されているがんバイオマーカーの特徴や応用について紹介する。(著者抄録)

  • 【大腸癌診療におけるprecision medicine】大腸癌患者の血清miRNAを用いた術前リンパ節転移予測診断能の意義について

    森谷 弘乃介, 松崎 潤太郎, 高見澤 康之, 坂本 良平, 塚本 俊輔, 志田 大, 金光 幸秀

    癌の臨床 ((株)篠原出版新社)  65 ( 4 ) 345 - 351 2021.01

    ISSN  0021-4949

  • 血液マイクロRNAによる子宮肉腫と変性筋腫の術前鑑別診断

    加藤 友康, 横井 暁, 松崎 潤太郎, 山本 雄介, 舘 慶生, 米岡 完, 清水 華子, 植原 貴史, 石川 光也, 滝澤 聡子, 青木 良晃, 加藤 健, 落谷 孝広, 東レ株式会社新事業開発部門DNAチップG

    日本婦人科腫瘍学会雑誌 ((公社)日本婦人科腫瘍学会)  39 ( 1 ) 297 - 297 2021.01

    ISSN  1347-8559

display all >>

Presentations 【 Display / hide

  • Prediction of cancer tissue of origin by circulating miRNA profiles

    The 12th Scientific Workshop of the Early Detection Research Network, 2021.03

  • Prospects of cancer diagnosis by circulation miRNA profiles

    International Session 5 “Innovative technology for next generation liquid biopsy” 第78回日本癌学会学術総会, 2019.09

  • 低分子化合物を用いた成熟肝・膵実質細胞の前駆細胞へのリプログラミング技術の開発

    一般口演19 「細胞-1/口腔/酸化ストレス」. 第19回日本抗加齢医学会総会, 2019.06

  • 低分子化合物による膵外分泌細胞の膵前駆様細胞およびインスリン分泌細胞の誘導

    口演33 「膵臓2」. 第18回日本再生医療学会総会, 2019.03

  • Circulating microRNA profiling for the detection of cancers: recent progress

    The 34th Joint Annual Conference of Biomedical Science, 2019.03

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • CRISPR-Cas9 based screening for essential tumor suppressors in liver carcinogenesis


    National Cancer Center Japan, Yamamoto Yusuke, 松崎 潤太郎, Grant-in-Aid for Challenging Research (Exploratory)

     View Summary

    A large number of research projects identified genetic mutations in the process of carcinogenesis, and there have been some useful findings of studies using cancer cell lines. With next generation sequencing, genetic variants in a variety of cancers have been identified and shown to have an impact on carcinogenesis; however, it is still unclear how the mutations essentially influenced the carcinogenesis and their metastatic potential. In this research project, we introduced and quantitatively analyzed the contribution of genetic mutations involved in the carcinogenic process by CRISPR-Cas9, in order to knockout the tumor suppressor genes in primary epithelial cells, and examined the effect of each gene on carcinogenesis. Also, we tried to recapitulate the multi-step carcinogenesis in vitro. This study enables us to accurately reflect and reproduce genomic aberrations in normal cells, and to achieve validation of the actual function of driver gene mutations.

  • Identification of circulating microRNAs for the detection of early stage pancreatic cancer


    MEXT,JSPS, Grant-in-Aid for Scientific Research, 松崎 潤太郎, Grant-in-Aid for Scientific Research (C), Principal Investigator

     View Summary

    本研究は、初代分離培養した膵外分泌細胞に対して低分子化合物を曝露させ、in vitroでパーシャルリプログラミングを行って膵前駆細胞を樹立し、この細胞に胆汁酸によるストレス刺激を与えることで膵発がん初期の環境をin vitroでモデル化し、膵発がん超初期のバイオマーカーとなるmicroRNAの同定を試みるものである。我々はラットおよびマウスの膵外分泌細胞を用いて、特定の低分子化合物のコンビネーションが膵前駆細胞を誘導することを見出したが、一方で誘導された膵前駆細胞の性能を、Pdx1やNkx6.1といったマーカー分子で評価したところ、実験ロットによって均質でないことを見出した。そこでsingle cell sortingによって、膵前駆細胞としてより機能的に優れた細胞のクローン化を試み、これに成功した。驚くべきことに、この膵前駆細胞は特定の培養環境下においてインスリンを分泌する細胞にも分化し得た。また膵外分泌細胞よりDBAレクチンを用いて分取した膵管上皮細胞が膵前駆細胞の由来細胞であることも見出した。

  • Generation of hepatic progenitor cells from human hepatocytes using small molecules


    National Cancer Center Japan, KATSUDA Takeshi, OCHIYA Takahiro, MATSUZAKI Juntaro, SAITO Yoshimasa, TAKEUCHI Atsuko, Grant-in-Aid for Young Scientists (B)

     View Summary

    Using small molecule inhibitors, we recently reported that rodent mature hepatocytes can be reprogrammed into progenitor-like phenotype with repopulative capacity. In this study, using the same strategy, we demonstrated that hepatic progenitor cells can be induced from human infant hepatocytes. These cells, named human chemically induced progenitors (hCLiPs), exhibited significant repopulative capacity in injured mouse livers following transplantation, and contributed to reconstruction of the normal liver architecture. We also found that hCLiPs can be redifferentiated into mature hepatocytes in vitro with hepatic inducible factors. These redifferentiated cells can be induced to exhibit cytochrome P450 (CYP) enzymatic activities in response to the CYP inducing molecules with the efficiency comparable with that of primary hepatocytes. Thus, this study contributes to progress in the field of liver cell transplantation therapy and pharmacological research field.

  • Interaction of miR-221/222 and adipocytokine signaling in esophageal adenocarcinoma


    Keio University, Matsuzaki Juntaro, TSUGAWA Hitoshi, SUZUKI Hidekazu, Grant-in-Aid for Young Scientists (B)

     View Summary

    Esophageal adenocarcinoma, which is rapidly increasing in Western countries, is one of the complications of gastroesophageal reflux disease. Bile reflux and central obesity are major risk factors for esophageal adenocarcinoma. In general, plasma adiponectin levels are decreased through the progression of central obesity. We had reported that bile acids contribute to carcinogenesis through the activation of nuclear bile acid receptor (FXR) and the enhancement of miR-221/222. Herein, we identified that miR-221/222 enhance the expression of COX-2 in esophageal epithelial cells. On the other hand, COX-2 expression was suppressed during exposure to adiponectin receptor agonist. These results suggest adiponectin receptor agonist might work as a chemopreventive agent for esophageal adenocarcinoma among high-risk individuals with central obesity.

  • 食道腺がん治療標的としてのCDX2分解系とmiR-221/222の重要性の解明


    Keio University, 松崎 潤太郎, Grant-in-Aid for Young Scientists (B)

Awards 【 Display / hide

  • 日本癌学会奨励賞


    Type of Award: Awards of National Conference, Council and Symposium

  • the 15th Korea-Japan Joint Symposium on Helicobacter infection Young Investigator Award


    Type of Award: Awards of International Conference, Council and Symposium

  • United European Gastroenterology Week (UEGW) 2016 Poster of Excellence


    Type of Award: Awards of International Conference, Council and Symposium

  • 第18回日本神経消化器病学会・第6回IBS研究会・第84回消化器心身医学研究会・第10回機能性ディスペプシア研究会合同学術集会 並木賞


    Type of Award: Awards of National Conference, Council and Symposium

  • 4th Biennial Congress of Asian Neurogastroenterology & Motility Association (ANMA) Best Poster Presentation Award


    Type of Award: Awards of International Conference, Council and Symposium

display all >>


Courses Taught 【 Display / hide











display all >>


Committee Experiences 【 Display / hide

  • 2019


  • 2018